Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: A single institution experience.

e12662Background: Androgen receptor (AR) expression has recently emerged as a potential prognostic and predictive marker in patients with triple negative breast cancer (TNBC). We conducted a retrospective analysis in our institution to evaluate pathologic complete response (pCR) rates, disease-free survival (DFS) and overall survival (OS) in both AR positive and AR negative TNBC patients treated with neoadjuvant chemotherapy over 10 years. Methods: 107 patients with TNBC subtype, treated between June 2006 and March 2016 were evaluated for AR expression. Fifty-eight tumor specimens were available, and stained immunohistochemically, with twenty being AR-positive (⩾10% nuclear stained cells) and thirty-eight being AR negative. Correlation of AR expression was examined with various prognostic factors and outcomes. Results: For the cohort of 58 patients, median age was 49 years. Median follow up was 49 months. All patients received anthracycline based chemotherapy with 23% receiving an additional platinum chem...